Ikena Oncology, Inc. (IKNA): Price and Financial Metrics
IKNA Price/Volume Stats
Current price | $1.71 | 52-week high | $2.32 |
Prev. close | $1.74 | 52-week low | $1.22 |
Day low | $1.70 | Volume | 9,648 |
Day high | $1.73 | Avg. volume | 244,357 |
50-day MA | $1.71 | Dividend yield | N/A |
200-day MA | $1.57 | Market Cap | 82.52M |
IKNA Stock Price Chart Interactive Chart >
Ikena Oncology, Inc. (IKNA) Company Bio
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
IKNA Price Returns
1-mo | 0.00% |
3-mo | 0.00% |
6-mo | 19.58% |
1-year | 22.14% |
3-year | -89.44% |
5-year | N/A |
YTD | -13.20% |
2023 | -25.94% |
2022 | -78.79% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...